oxidopamine has been researched along with Developmental Psychomotor Disorders in 2 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, W | 1 |
| Goshima, Y | 1 |
| Ohshima, T | 1 |
| Glajch, KE | 1 |
| Fleming, SM | 1 |
| Surmeier, DJ | 1 |
| Osten, P | 1 |
2 other studies available for oxidopamine and Developmental Psychomotor Disorders
| Article | Year |
|---|---|
Loss of Collapsin Response Mediator Protein 4 Attenuates 6-Hydroxydopamine-Induced Impairments in a Mouse Model of Parkinson's Disease.
Topics: Animals; Caspase 3; Cyclooxygenase 2; Dopaminergic Neurons; Gene Deletion; Genetic Therapy; Male; Mi | 2020 |
Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Disease Models, Animal; Dopaminergic Neurons; Gait Disorders, Neurologic | 2012 |